Singapore Institute of Advanced Medicine Holdings (SIAMH) has announced that it has lodged its preliminary offer document in connection with its proposed initial public offering (IPO) and listing on the Catalist of the Singapore Exchange S68 Securities Trading Limited (SGX-ST) on Nov 23.
Bursa-listed property developer Berjaya Corporation is the majority owner of SIAMH, its subsidiary.
SIAMH is a healthcare service provider using advanced technology for early and accurate diagnosis and offering appropriate treatments for a wide spectrum of diseases and health conditions including cancer and neurodegenerative and cardiovascular diseases.
Headquartered in Singapore, SIAMH currently operates at Biopolis Drive and Lucky Plaza offering services in medical diagnostics and treatments, radiation therapy and medical oncology services. The group aims to create a comprehensive one-stop ambulatory cancer centre.
SIAMH has long-standing relationships with global companies in advanced medical and healthcare technology, which are its suppliers, as well as private and public institutions. The group’s clinic at Biopolis Drive is also a reference site for Philips Electronics Singapore regarding the use and functions of Philips’ equipment and solutions in clinical settings.
The group focuses on the use of industry-leading and advanced technologies in the provision of healthcare services, and aspires to offer the most appropriate treatments to achieve better outcomes for its patients.
See also: Food Innovators Holdings lodges preliminary offer document for Catalist listing
Dr Djeng Shih Kien, CEO and founder of SIAMH, says: “Cancer has been one of the leading causes of death in Singapore over the past few years, and the word instils fear and anxiety. We are attempting to change this by providing early and accurate diagnosis and treatment using advanced medical technologies. We aim to create a comprehensive one-stop ambulatory cancer centre to enhance the patient’s journey and improve their quality of life.”
Djeng notes that SIAMH collaborates with global companies and top institutions, both public and private, to constantly invest in R&D and advanced technologies. The group has also assembled a dedicated team of professionals and experts to create a “synergetic ecosystem to deliver a seamless patient experience”.
“The proposed initial public offering will enable us to accelerate our growth through the rapidly growing oncology market. With advanced technologies at our disposal, we are strategically positioned to capture the thriving Singapore market driven by medical tourism,” he adds.
